Interpace Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2026. The company reported total revenue of $10.4 million for the quarter, representing an 18% increase compared to the same period in the prior year. This revenue growth was driven by a 7% increase in thyroid test volume and an 18% increase in thyroid revenue year-over-year.
On a trailing twelve-month basis, thyroid revenue reached $38.0 million, an increase of approximately 13% over the comparable prior twelve-month period. The company’s gross margin expanded to 69% in Q3 2026, up from 62% in the prior year quarter. This expansion in gross margin contributed to an increase in Adjusted EBITDA to $2.1 million, or approximately 20% of revenue, compared to $1.3 million, or 14% of revenue, in the prior year quarter.
Despite the operational improvements, the company reported a loss from continuing operations of $1.5 million for the quarter. This loss included approximately $4.1 million in non-recurring stock compensation costs and non-recurring legal expenses, which are excluded from Adjusted EBITDA. The company noted that it operates as a thyroid-only molecular diagnostics company following the discontinuation of its PancraGEN pancreatic testing business in May 2025.
Management highlighted continued investments in laboratory automation and AI-enabled productivity initiatives. These investments resulted in an approximately 11% improvement in the average turnaround time for ThyGeNEXT and ThyraMIR v2 tests during the first nine months of 2026 compared to the prior year period. The company also provided an update on its pancreatic cancer program, stating that analytical validation of the panel design is underway, though the program is not expected to contribute revenue in 2026 or 2027.